aspirin has been researched along with Abnormality, Heart in 56 studies
Aspirin: The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5)
acetylsalicylate : A benzoate that is the conjugate base of acetylsalicylic acid, arising from deprotonation of the carboxy group.
acetylsalicylic acid : A member of the class of benzoic acids that is salicylic acid in which the hydrogen that is attached to the phenolic hydroxy group has been replaced by an acetoxy group. A non-steroidal anti-inflammatory drug with cyclooxygenase inhibitor activity.
Excerpt | Relevance | Reference |
---|---|---|
"To determine the cardiovascular outcomes in high risk patients with osteoarthritis treated with ibuprofen, naproxen or lumiracoxib." | 9.12 | Cardiovascular outcomes in high risk patients with osteoarthritis treated with ibuprofen, naproxen or lumiracoxib. ( Abramson, SB; Chesebro, JH; Farkouh, ME; Fuster, V; Greenberg, JD; Hochman, JS; Jeger, RV; Kirshner, H; Lay, CL; Matchaba, PT; Mellein, B; Ramanathan, K; Ruland, S; Verheugt, FW, 2007) |
"The purpose of this study was to determine, on the basis of published reports, whether aspirin use during the first trimester of pregnancy is associated with an increased risk of congenital malformations." | 8.81 | Aspirin consumption during the first trimester of pregnancy and congenital anomalies: a meta-analysis. ( Boskovic, R; Costei, A; Koren, G; Kozer, E; Nikfar, S; Nulman, I, 2002) |
"Postoperative thrombosis is associated with aspirin unresponsiveness in this patient population." | 7.80 | Aspirin unresponsiveness predicts thrombosis in high-risk pediatric patients after cardiac surgery. ( Baird, CW; Emani, S; Emani, SM; Fynn-Thompson, FE; Pigula, FA; Trainor, B; Zurakowski, D, 2014) |
"Aspirin is used to prevent thromboembolism in children with heart disease without evidence supporting its efficacy." | 7.74 | Aspirin resistance in children with heart disease at risk for thromboembolism: prevalence and possible mechanisms. ( Fixler, DE; Heistein, LC; Journeycake, JM; Lemler, MS; Ramaciotti, C; Scott, WA; Zellers, TM, 2008) |
"It has been hypothesized that the ingestion of aspirin by women during pregnancy increases their infants' risk of certain congenital heart defects." | 7.67 | The relation of aspirin use during the first trimester of pregnancy to congenital cardiac defects. ( Mitchell, AA; Shapiro, S; Werler, MM, 1989) |
"To determine the cardiovascular outcomes in high risk patients with osteoarthritis treated with ibuprofen, naproxen or lumiracoxib." | 5.12 | Cardiovascular outcomes in high risk patients with osteoarthritis treated with ibuprofen, naproxen or lumiracoxib. ( Abramson, SB; Chesebro, JH; Farkouh, ME; Fuster, V; Greenberg, JD; Hochman, JS; Jeger, RV; Kirshner, H; Lay, CL; Matchaba, PT; Mellein, B; Ramanathan, K; Ruland, S; Verheugt, FW, 2007) |
" Some are beginning to broaden prenatal screening to include pregnancy complications such as pre-eclampsia that can be prevented using soluble low-dose aspirin treatment started before 16 weeks of gestation." | 4.93 | Development of prenatal screening--A historical overview. ( Cuckle, H; Maymon, R, 2016) |
"The purpose of this study was to determine, on the basis of published reports, whether aspirin use during the first trimester of pregnancy is associated with an increased risk of congenital malformations." | 4.81 | Aspirin consumption during the first trimester of pregnancy and congenital anomalies: a meta-analysis. ( Boskovic, R; Costei, A; Koren, G; Kozer, E; Nikfar, S; Nulman, I, 2002) |
" Bleeding rates were high in both groups; however, bleeding was more frequent in the warfarin group." | 4.02 | Long-term outcomes of warfarin versus aspirin after Fontan surgery. ( Attard, C; Briody, J; Cordina, R; d'Udekem, Y; Hassan, EB; Ignjatovic, V; Mackay, MT; Monagle, PT; Rice, K; Simm, P, 2021) |
" Additionally, he had undergone an aortic root dilatation and aortic valve replacement at the age of 10 because of progression of aortic and supra-aortic stenosis and had received chronic anticoagulation and antiplatelet therapy with warfarin and aspirin, respectively." | 4.02 | Spontaneous Spinal Epidural Hematoma in an Adult Patient with Complex Congenital Heart Disease. ( Ifuku, T; Nishiguchi, T, 2021) |
"There are few data to guide aspirin therapy to prevent shunt thrombosis in infants." | 3.85 | Platelet Inhibition in Shunted Infants on Aspirin at Short and Midterm Follow-Up. ( Bailly, DK; Burch, PT; Clawson, JR; Johnson, JT; LuAnn Minich, L; Sheng, X; Truong, DT; Witte, MK, 2017) |
"To characterize platelet function and responsiveness to aspirin in relation to thrombogenesis, systemic inflammation, and markers of endothelial function in adults with Fontan circulation (FC)." | 3.81 | Aspirin resistance in adult patients after Fontan surgery. ( Chłopicki, S; Komar, M; Musiałek, P; Olszowska, M; Pajak, J; Podolec, J; Podolec, P; Rubis, P; Sitek, B; Tomkiewicz-Pajak, L; Wojcik, T, 2015) |
" Centers with best outcomes implement aspirin earlier in their postoperative shunt thrombosis prophylaxis regimen." | 3.80 | Defining the best practice patterns for the neonatal systemic-to-pulmonary artery shunt procedure. ( Brar, A; Eghtesady, P; Hall, M; Heidari-Bateni, G; Norouzi, S, 2014) |
"Postoperative thrombosis is associated with aspirin unresponsiveness in this patient population." | 3.80 | Aspirin unresponsiveness predicts thrombosis in high-risk pediatric patients after cardiac surgery. ( Baird, CW; Emani, S; Emani, SM; Fynn-Thompson, FE; Pigula, FA; Trainor, B; Zurakowski, D, 2014) |
"Aspirin is often used to prevent thrombosis in pediatric cardiac surgery." | 3.76 | Aspirin resistance following pediatric cardiac surgery. ( Alfieris, GM; Blumberg, N; Cholette, JM; Lerner, NB; Mamikonian, L, 2010) |
"Aspirin is used to prevent thromboembolism in children with heart disease without evidence supporting its efficacy." | 3.74 | Aspirin resistance in children with heart disease at risk for thromboembolism: prevalence and possible mechanisms. ( Fixler, DE; Heistein, LC; Journeycake, JM; Lemler, MS; Ramaciotti, C; Scott, WA; Zellers, TM, 2008) |
"It has been hypothesized that the ingestion of aspirin by women during pregnancy increases their infants' risk of certain congenital heart defects." | 3.67 | The relation of aspirin use during the first trimester of pregnancy to congenital cardiac defects. ( Mitchell, AA; Shapiro, S; Werler, MM, 1989) |
"Testing platelet function makes clopidogrel dosing safer, and simplifies therapy adjustments in long-term treatment." | 2.77 | Prophylactic use of clopidogrel in paediatric cardiac patients. ( Grohmann, J; Hanke, CA; Nakamura, L; Stiller, B; Zieger, B, 2012) |
" Inadequate initial dosing appears to be the primary reason for aspirin resistance." | 1.72 | Aspirin resistance in infants with shunt-dependent congenital heart disease. ( Cooper, DS; Henry, B; Koh, W; Nebbia, A; Rodts, M; Sawyer, J, 2022) |
"Aspirin resistance was defined as platelet inhibition below 50%." | 1.51 | Prevalence of aspirin resistance by thromboelastography plus platelet mapping in children with CHD: a single-centre experience. ( Bartakian, S; Berganza, FM; Brownlee, J; Egbe, AC; Gonzalez de Alba, C, 2019) |
" A randomised trial is needed to determine appropriate acetylsalicylic acid dosing in infants with modified Blalock-Taussig." | 1.51 | High acetylsalicylic acid dosing in infants after modified Blalock-Taussig shunt. ( Allen, J; Boston, US; Cowan, KM; Jones, T; Joshi, AD; Knott-Craig, CJ; Kumar, STK; Nouer, SS; Saini, A; Shah, SH; Wayne Gatewood, C, 2019) |
" Unlike general toxicity data, their prenatal toxic effects were not extensively studied before." | 1.33 | Comparison of developmental toxicity of selective and non-selective cyclooxygenase-2 inhibitors in CRL:(WI)WUBR Wistar rats--DFU and piroxicam study. ( Burdan, F, 2005) |
"Aspirin was discontinued on the personal decision of individual physicians." | 1.30 | Reduced frequency of occlusion of aorto-pulmonary shunts in infants receiving aspirin. ( Bürsch, J; Motz, R; Ruschewski, W; Wessel, A, 1999) |
" Optimum drug or combination of drugs and dosage are still controversial." | 1.26 | [Inhibition of platelet function in pediatric medicine (author's transl)]. ( Schmidt, B, 1982) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 13 (23.21) | 18.7374 |
1990's | 7 (12.50) | 18.2507 |
2000's | 10 (17.86) | 29.6817 |
2010's | 22 (39.29) | 24.3611 |
2020's | 4 (7.14) | 2.80 |
Authors | Studies |
---|---|
Song, QQ | 1 |
Zhu, LH | 1 |
Chen, OY | 1 |
Xiao, ZR | 1 |
Chen, Z | 1 |
Xiao, YB | 1 |
Meng, JC | 1 |
Zuo, C | 1 |
Latour, JM | 1 |
Attard, C | 3 |
Monagle, PT | 1 |
d'Udekem, Y | 3 |
Mackay, MT | 1 |
Briody, J | 1 |
Cordina, R | 1 |
Hassan, EB | 1 |
Simm, P | 1 |
Rice, K | 1 |
Ignjatovic, V | 2 |
Ifuku, T | 1 |
Nishiguchi, T | 1 |
Koh, W | 1 |
Rodts, M | 1 |
Nebbia, A | 1 |
Sawyer, J | 1 |
Henry, B | 1 |
Cooper, DS | 1 |
Zhou, C | 1 |
Guo, X | 1 |
Cui, Q | 1 |
Liu, X | 1 |
Su, G | 1 |
Zhang, J | 1 |
Huang, J | 1 |
Monagle, P | 1 |
Uber, AM | 1 |
Montez-Rath, ME | 1 |
Kwiatkowski, DM | 1 |
Krawczeski, CD | 1 |
Sutherland, SM | 1 |
Berganza, FM | 1 |
Gonzalez de Alba, C | 1 |
Egbe, AC | 1 |
Bartakian, S | 1 |
Brownlee, J | 1 |
Saini, A | 1 |
Joshi, AD | 1 |
Cowan, KM | 1 |
Wayne Gatewood, C | 1 |
Kumar, STK | 1 |
Allen, J | 1 |
Shah, SH | 1 |
Nouer, SS | 1 |
Jones, T | 1 |
Knott-Craig, CJ | 1 |
Boston, US | 1 |
Potter, BJ | 1 |
Leong-Sit, P | 1 |
Fernandes, SM | 1 |
Feifer, A | 1 |
Mayer, JE | 1 |
Triedman, JK | 1 |
Walsh, EP | 1 |
Landzberg, MJ | 1 |
Khairy, P | 1 |
Seckeler, MD | 1 |
D'Souza, MD | 1 |
Gangemi, JJ | 1 |
Hoyer, AW | 1 |
Jayakumar, KA | 1 |
Alizade, E | 1 |
Çağan Efe, S | 1 |
Kutlutürk, I | 1 |
Fidan, S | 1 |
Avcı, A | 1 |
Metin Esen, A | 1 |
Heidari-Bateni, G | 1 |
Norouzi, S | 1 |
Hall, M | 1 |
Brar, A | 1 |
Eghtesady, P | 1 |
Emani, S | 1 |
Trainor, B | 1 |
Zurakowski, D | 1 |
Baird, CW | 1 |
Fynn-Thompson, FE | 1 |
Pigula, FA | 1 |
Emani, SM | 1 |
Wilson, SR | 1 |
Kronzon, I | 1 |
Machnicki, SC | 1 |
Ruiz, CE | 1 |
Tomkiewicz-Pajak, L | 1 |
Wojcik, T | 1 |
Chłopicki, S | 1 |
Olszowska, M | 1 |
Pajak, J | 1 |
Podolec, J | 1 |
Sitek, B | 1 |
Musiałek, P | 1 |
Rubis, P | 1 |
Komar, M | 1 |
Podolec, P | 1 |
Cuckle, H | 1 |
Maymon, R | 1 |
Iyengar, AJ | 1 |
Winlaw, DS | 1 |
Galati, JC | 1 |
Wheaton, GR | 1 |
Gentles, TL | 1 |
Grigg, LE | 1 |
Justo, RN | 1 |
Radford, DJ | 1 |
Weintraub, RG | 1 |
Bullock, A | 1 |
Sholler, GS | 1 |
Celermajer, DS | 1 |
Truong, DT | 1 |
Johnson, JT | 1 |
Bailly, DK | 1 |
Clawson, JR | 1 |
Sheng, X | 1 |
Burch, PT | 1 |
Witte, MK | 1 |
LuAnn Minich, L | 1 |
Protopapas, AD | 1 |
Athanasiou, T | 1 |
Gordon, BM | 1 |
Moore, JW | 1 |
Fouladkou, F | 1 |
Lu, C | 1 |
Jiang, C | 1 |
Zhou, L | 1 |
She, Y | 1 |
Walls, JR | 1 |
Kawabe, H | 1 |
Brose, N | 1 |
Henkelman, RM | 1 |
Huang, A | 1 |
Bruneau, BG | 1 |
Rotin, D | 1 |
Ganigara, M | 1 |
Prabhu, A | 1 |
Varghese, R | 1 |
Pavithran, S | 1 |
Valliatu, J | 1 |
Nair, RS | 1 |
Cholette, JM | 1 |
Mamikonian, L | 1 |
Alfieris, GM | 1 |
Blumberg, N | 1 |
Lerner, NB | 1 |
Hanke, CA | 1 |
Stiller, B | 1 |
Nakamura, L | 1 |
Grohmann, J | 1 |
Zieger, B | 1 |
Gokce, M | 1 |
Altan, I | 1 |
Unal, S | 1 |
Kuskonmaz, B | 1 |
Aytac, S | 1 |
Cetin, M | 1 |
Tuncer, M | 1 |
Gumruk, F | 1 |
Gurgey, A | 1 |
Romlin, BS | 1 |
Wåhlander, H | 1 |
Strömvall-Larsson, E | 1 |
Synnergren, M | 1 |
Baghaei, F | 1 |
Jeppsson, A | 1 |
Kozer, E | 1 |
Nikfar, S | 1 |
Costei, A | 1 |
Boskovic, R | 1 |
Nulman, I | 1 |
Koren, G | 1 |
Sideris, EB | 1 |
Luo, XJ | 1 |
Yan, J | 1 |
Wu, QY | 1 |
Yang, KM | 1 |
Xu, JP | 1 |
Liu, YL | 1 |
Burdan, F | 1 |
Barker, PC | 1 |
Nowak, C | 1 |
King, K | 1 |
Mosca, RS | 1 |
Bove, EL | 1 |
Goldberg, CS | 1 |
Farkouh, ME | 1 |
Greenberg, JD | 1 |
Jeger, RV | 1 |
Ramanathan, K | 1 |
Verheugt, FW | 1 |
Chesebro, JH | 2 |
Kirshner, H | 1 |
Hochman, JS | 1 |
Lay, CL | 1 |
Ruland, S | 1 |
Mellein, B | 1 |
Matchaba, PT | 1 |
Fuster, V | 2 |
Abramson, SB | 1 |
Li, JS | 1 |
Yow, E | 1 |
Berezny, KY | 1 |
Rhodes, JF | 1 |
Bokesch, PM | 1 |
Charpie, JR | 1 |
Forbus, GA | 1 |
Mahony, L | 1 |
Boshkov, L | 1 |
Lambert, V | 1 |
Bonnet, D | 1 |
Michel-Behnke, I | 1 |
Graham, TP | 1 |
Takahashi, M | 1 |
Jaggers, J | 1 |
Califf, RM | 1 |
Rakhit, A | 1 |
Fontecave, S | 1 |
Sanders, SP | 1 |
Heistein, LC | 1 |
Scott, WA | 1 |
Zellers, TM | 1 |
Fixler, DE | 1 |
Ramaciotti, C | 1 |
Journeycake, JM | 1 |
Lemler, MS | 1 |
Agarwal, KC | 1 |
Wahner, HW | 1 |
Dewanjee, MK | 1 |
Puga, FJ | 1 |
Danielson, GK | 1 |
Feldt, RH | 1 |
Willoughby, ML | 1 |
Schmidt, B | 2 |
Fiane, AE | 1 |
Seem, E | 1 |
Geiran, O | 1 |
Lindberg, HL | 1 |
Malouf, JF | 1 |
Alam, S | 1 |
Gharzeddine, W | 1 |
Stefadouros, MA | 1 |
Centazzo, S | 1 |
Montigny, M | 1 |
Davignon, A | 1 |
Chartrand, C | 1 |
Fournier, A | 1 |
Marchand, T | 1 |
Ammash, N | 1 |
Warnes, CA | 1 |
Motz, R | 1 |
Wessel, A | 1 |
Ruschewski, W | 1 |
Bürsch, J | 1 |
Rudolph, AM | 2 |
Heymann, MA | 2 |
Sutor, H | 1 |
Lorenz, H | 1 |
Tikkanen, J | 1 |
Heinonen, OP | 1 |
Raub, W | 1 |
Werler, MM | 1 |
Mitchell, AA | 1 |
Shapiro, S | 1 |
Sherman, DG | 1 |
Dyken, ML | 1 |
Fisher, M | 1 |
Harrison, MJ | 1 |
Hart, RG | 1 |
Zierler, S | 1 |
Rothman, KJ | 1 |
Palmer, AK | 2 |
Goldschmidt, B | 1 |
Sorland, SJ | 1 |
Bjornstad, PG | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
Aspirin for the Prevention of Preeclampsia in Women With Stage 1 Hypertension: A Pilot Study[NCT04908982] | Phase 4 | 60 participants (Anticipated) | Interventional | 2021-05-28 | Recruiting | ||
Aspirin Supplementation for Pregnancy Indicated Risk Reduction In Nulliparas (ASPIRIN)[NCT02409680] | 11,976 participants (Actual) | Interventional | 2016-03-23 | Completed | |||
Antiplatelet Activity of Aspirin in Infants After Aortopulmonary and Cavopulmonary Shunts[NCT01656993] | 25 participants (Actual) | Observational | 2012-11-30 | Completed | |||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
- Early preterm delivery (<34 weeks) (NCT02409680)
Timeframe: At delivery
Intervention | Participants (Count of Participants) |
---|---|
Intervention Arm | 189 |
Placebo Arm | 230 |
- Birth weight <2500g (NCT02409680)
Timeframe: At delivery
Intervention | Participants (Count of Participants) |
---|---|
Intervention Arm | 1078 |
Placebo Arm | 1153 |
- Birth weight <1500g (NCT02409680)
Timeframe: At delivery
Intervention | Participants (Count of Participants) |
---|---|
Intervention Arm | 78 |
Placebo Arm | 101 |
- Incidence of Fetal Loss (NCT02409680)
Timeframe: At delivery
Intervention | Participants (Count of Participants) |
---|---|
Intervention Arm | 303 |
Placebo Arm | 353 |
- Incidence of Spontaneous Abortion (NCT02409680)
Timeframe: At delivery
Intervention | Participants (Count of Participants) |
---|---|
Intervention Arm | 134 |
Placebo Arm | 152 |
- Incidence of All stillbirth (NCT02409680)
Timeframe: At delivery
Intervention | Participants (Count of Participants) |
---|---|
Intervention Arm | 141 |
Placebo Arm | 166 |
- Incidence of Medical Termination of Pregnancy (NCT02409680)
Timeframe: At delivery
Intervention | Participants (Count of Participants) |
---|---|
Intervention Arm | 42 |
Placebo Arm | 30 |
- Hypertensive disorders of pregnancy is defined by the characterization of evidence of a hypertensive disorder, including either preeclampsia or eclampsia occurring during the pregnancy. (NCT02409680)
Timeframe: Evidence of hypertensive disorder during the pregnancy (prior to delivery/birth)
Intervention | Participants (Count of Participants) |
---|---|
Intervention Arm | 352 |
Placebo Arm | 325 |
- Incidence of Perinatal Mortality (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery
Intervention | Participants (Count of Participants) |
---|---|
Intervention Arm | 264 |
Placebo Arm | 309 |
The primary outcome of this study is incidence of preterm birth, which will be defined as delivery at or after 20 0/7 weeks and prior to 37 0/7 weeks. This will be determined based on actual date of delivery in comparison to the projected estimated due date (EDD), independent of whether or not the preterm delivery is indicated or spontaneous. (NCT02409680)
Timeframe: At delivery
Intervention | Participants (Count of Participants) |
---|---|
Intervention Arm | 668 |
Placebo Arm | 754 |
- Small for gestational age (SGA) as defined by the INTERGROWTH-21st standard (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery
Intervention | Participants (Count of Participants) |
---|---|
Intervention Arm | 1506 |
Placebo Arm | 1564 |
- Vaginal bleeding (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery
Intervention | Participants (Count of Participants) |
---|---|
Intervention Arm | 214 |
Placebo Arm | 246 |
- Antepartum hemorrhage (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery
Intervention | Participants (Count of Participants) |
---|---|
Intervention Arm | 26 |
Placebo Arm | 25 |
- Postpartum hemorrhage (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery
Intervention | Participants (Count of Participants) |
---|---|
Intervention Arm | 54 |
Placebo Arm | 43 |
- Incidence of Maternal Mortality (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery
Intervention | Participants (Count of Participants) |
---|---|
Intervention Arm | 9 |
Placebo Arm | 12 |
- Incidence of Late Abortion (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery
Intervention | Participants (Count of Participants) |
---|---|
Intervention Arm | 23 |
Placebo Arm | 30 |
Hemoglobin < 7.0 gm/dl at 26-30 weeks gestation or a drop of 3.5+ gm/dl from screening to 26-30 weeks gestation (NCT02409680)
Timeframe: At enrollment, 4 weeks post enrollment, and 26-30 weeks GA.
Intervention | Participants (Count of Participants) |
---|---|
Intervention Arm | 290 |
Placebo Arm | 333 |
Early preterm delivery (<34 weeks) and hypertensive disorders (i.e.: preeclampsia) (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery
Intervention | Participants (Count of Participants) |
---|---|
Intervention Arm | 8 |
Placebo Arm | 21 |
6 reviews available for aspirin and Abnormality, Heart
Article | Year |
---|---|
Pathophysiology of thrombosis and anticoagulation post Fontan surgery.
Topics: Anticoagulants; Aspirin; Fibrinolytic Agents; Fontan Procedure; Heart Defects, Congenital; Humans; T | 2018 |
Development of prenatal screening--A historical overview.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Biomarkers; Cell-Free System; DNA; Down Syndrome; | 2016 |
Contegra conduit for reconstruction of the right ventricular outflow tract: a review of published early and mid-time results.
Topics: Aspirin; Bioprosthesis; Blood Vessel Prosthesis; Blood Vessel Prosthesis Implantation; Fibrinolytic | 2008 |
Aspirin consumption during the first trimester of pregnancy and congenital anomalies: a meta-analysis.
Topics: Abnormalities, Drug-Induced; Aspirin; Case-Control Studies; Cohort Studies; Congenital Abnormalities | 2002 |
Aspirin consumption during the first trimester of pregnancy and congenital anomalies: a meta-analysis.
Topics: Abnormalities, Drug-Induced; Aspirin; Case-Control Studies; Cohort Studies; Congenital Abnormalities | 2002 |
Aspirin consumption during the first trimester of pregnancy and congenital anomalies: a meta-analysis.
Topics: Abnormalities, Drug-Induced; Aspirin; Case-Control Studies; Cohort Studies; Congenital Abnormalities | 2002 |
Aspirin consumption during the first trimester of pregnancy and congenital anomalies: a meta-analysis.
Topics: Abnormalities, Drug-Induced; Aspirin; Case-Control Studies; Cohort Studies; Congenital Abnormalities | 2002 |
[Congenital and acquired thrombocyte function disorders].
Topics: Aspirin; Blood Platelet Disorders; Dipyridamole; Fibrin Fibrinogen Degradation Products; Heart Defec | 1980 |
Cerebral embolism.
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Calcinosis; Cardiomyopathy, Hypertrophic; Clinical Tri | 1986 |
4 trials available for aspirin and Abnormality, Heart
Article | Year |
---|---|
Prophylactic use of clopidogrel in paediatric cardiac patients.
Topics: Aspirin; Child; Child, Preschool; Clopidogrel; Dose-Response Relationship, Drug; Drug Therapy, Combi | 2012 |
Cardiovascular outcomes in high risk patients with osteoarthritis treated with ibuprofen, naproxen or lumiracoxib.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Cyclooxygenase 2 In | 2007 |
Cerebral embolism.
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Calcinosis; Cardiomyopathy, Hypertrophic; Clinical Tri | 1986 |
The effect of acetylsalicylic acid on platelet function in cyanotic congenital heart disease.
Topics: Adolescent; Aspirin; Blood Cell Count; Blood Coagulation; Blood Platelets; Child; Child, Preschool; | 1974 |
47 other studies available for aspirin and Abnormality, Heart
Article | Year |
---|---|
Compliance with aspirin in paediatric CHD post-percutaneous transcatheter occlusion: a cross-sectional study.
Topics: Aspirin; Caregivers; Child; Cross-Sectional Studies; Health Knowledge, Attitudes, Practice; Heart De | 2020 |
Long-term outcomes of warfarin versus aspirin after Fontan surgery.
Topics: Anticoagulants; Aspirin; Australia; Bone Density; Chemoprevention; Child; Cohort Studies; Female; Fo | 2021 |
Spontaneous Spinal Epidural Hematoma in an Adult Patient with Complex Congenital Heart Disease.
Topics: Adult; Anticoagulants; Aortic Valve Stenosis; Aspirin; Heart Defects, Congenital; Heart Septal Defec | 2021 |
Aspirin resistance in infants with shunt-dependent congenital heart disease.
Topics: Aspirin; Heart Defects, Congenital; Humans; Infant; Infant, Newborn; Thrombosis | 2022 |
Sildenafil improves the function of endothelial cells in patients suffering from congenital heart disease with pulmonary hypertension.
Topics: Adiponectin; Animals; Aspirin; Endothelial Cells; Endothelin-1; Enzyme-Linked Immunosorbent Assay; H | 2016 |
Nephrotoxin exposure and acute kidney injury in critically ill children undergoing congenital cardiac surgery.
Topics: Acute Kidney Injury; Adolescent; Aspirin; Cardiac Surgical Procedures; Child; Child, Preschool; Crit | 2018 |
Prevalence of aspirin resistance by thromboelastography plus platelet mapping in children with CHD: a single-centre experience.
Topics: Adolescent; Adult; Aspirin; Cardiac Surgical Procedures; Child; Child, Preschool; Drug Resistance; F | 2019 |
High acetylsalicylic acid dosing in infants after modified Blalock-Taussig shunt.
Topics: Administration, Oral; Aspirin; Blalock-Taussig Procedure; Computed Tomography Angiography; Dose-Resp | 2019 |
Effect of aspirin and warfarin therapy on thromboembolic events in patients with univentricular hearts and Fontan palliation.
Topics: Adolescent; Aspirin; Child; Child, Preschool; Cohort Studies; Female; Follow-Up Studies; Fontan Proc | 2013 |
Thrombotic occlusion of extracardiac conduit 4 months after Fontan surgery.
Topics: Aspirin; Child, Preschool; Drug Substitution; Drug Therapy, Combination; Fibrinolytic Agents; Fontan | 2013 |
Occlusion of the retinal artery occlusion by undiagnosed accessory mitral valve tissue.
Topics: Aspirin; Diagnosis, Differential; Echocardiography, Transesophageal; Embolism; Fluorescein Angiograp | 2014 |
Defining the best practice patterns for the neonatal systemic-to-pulmonary artery shunt procedure.
Topics: Aspirin; Bayes Theorem; Benchmarking; Cardiac Surgical Procedures; Chi-Square Distribution; Drug Adm | 2014 |
Aspirin unresponsiveness predicts thrombosis in high-risk pediatric patients after cardiac surgery.
Topics: Age Factors; Aspirin; Boston; Cardiac Surgical Procedures; Child, Preschool; Drug Resistance; Female | 2014 |
A constrained heart: a case of sudden onset unrelenting chest pain.
Topics: Analgesics, Opioid; Aspirin; Chest Pain; Clopidogrel; Coronary Angiography; Drug Therapy, Combinatio | 2014 |
Aspirin resistance in adult patients after Fontan surgery.
Topics: Adult; Aspirin; CD40 Antigens; Drug Resistance; Endothelium, Vascular; Female; Fontan Procedure; Hea | 2015 |
No difference between aspirin and warfarin after extracardiac Fontan in a propensity score analysis of 475 patients.
Topics: Anticoagulants; Aspirin; Australia; Female; Fontan Procedure; Heart Defects, Congenital; Hemorrhage; | 2016 |
Platelet Inhibition in Shunted Infants on Aspirin at Short and Midterm Follow-Up.
Topics: Aspirin; Cardiac Surgical Procedures; Female; Follow-Up Studies; Heart Defects, Congenital; Hemorrha | 2017 |
Nickel for your thoughts: Survey of the Congenital Cardiovascular Interventional Study Consortium (CCISC) for nickel allergy.
Topics: Alloys; Aspirin; Cardiac Catheterization; Data Collection; Drug Hypersensitivity; Female; Heart Defe | 2009 |
The ubiquitin ligase Nedd4-1 is required for heart development and is a suppressor of thrombospondin-1.
Topics: Animals; Aspirin; Endosomal Sorting Complexes Required for Transport; Female; Fibroblasts; Heart; He | 2010 |
Extracardiac Fontan operation after late bidirectional Glenn shunt.
Topics: Adolescent; Anticoagulants; Aspirin; Blood Pressure; Chest Tubes; Child; Child, Preschool; Drainage; | 2010 |
Aspirin resistance following pediatric cardiac surgery.
Topics: Administration, Oral; Administration, Rectal; Aspirin; Biomarkers; C-Reactive Protein; Cardiac Surgi | 2010 |
The devastating consequences of thrombosis of systemico pulmonary shunts and the blind administration of aspirin.
Topics: Aspirin; Cardiac Surgical Procedures; Drug Resistance; Evidence-Based Medicine; Fibrinolytic Agents; | 2010 |
Recurrent pediatric thrombosis: the effect of underlying and/or coexisting factors.
Topics: Adolescent; Adult; Anticoagulants; Aspirin; Child; Child, Preschool; Chronic Disease; Factor VIII; F | 2012 |
Monitoring of acetyl salicylic acid-induced platelet inhibition with impedance aggregometry in children with systemic-to-pulmonary shunts.
Topics: Aspirin; Blalock-Taussig Procedure; Double Outlet Right Ventricle; Electric Impedance; Female; Heart | 2013 |
TREATMENT of acute rheumatic fever in children a co-operative clinical trial of A.C.T.H., cortisone, and aspirin; a joint report by the Rheumatic Fever Working Party of the Medical Research Council of Great Britain and the Subcommittee of Principal Invest
Topics: Adrenocorticotropic Hormone; American Heart Association; Aspirin; Biomedical Research; Child; Cortis | 1955 |
Advances in transcatheter patch occlusion of heart defects.
Topics: Adolescent; Adult; Aspirin; Balloon Occlusion; Cardiac Catheterization; Catheters, Indwelling; Child | 2003 |
Clinical application of bidirectional Glenn shunt with off-pump technique.
Topics: Adolescent; Adult; Arteriovenous Shunt, Surgical; Aspirin; Blood Pressure; Cardiopulmonary Bypass; C | 2004 |
Comparison of developmental toxicity of selective and non-selective cyclooxygenase-2 inhibitors in CRL:(WI)WUBR Wistar rats--DFU and piroxicam study.
Topics: Abdominal Wall; Abnormalities, Drug-Induced; Alanine Transaminase; Animals; Aspartate Aminotransfera | 2005 |
Risk factors for cerebrovascular events following fontan palliation in patients with a functional single ventricle.
Topics: Aspirin; Cardiac Catheterization; Child, Preschool; Echocardiography; Female; Follow-Up Studies; Fon | 2005 |
Clinical outcomes of palliative surgery including a systemic-to-pulmonary artery shunt in infants with cyanotic congenital heart disease: does aspirin make a difference?
Topics: Aspirin; Cardiac Surgical Procedures; Heart Defects, Congenital; Humans; Infant; Palliative Care; Pr | 2007 |
Aspirin resistance in children with heart disease at risk for thromboembolism: prevalence and possible mechanisms.
Topics: Adolescent; Aspirin; Blood Platelets; Child; Child, Preschool; Dose-Response Relationship, Drug; Dru | 2008 |
Imaging of platelets in right-sided extracardiac conduits in humans.
Topics: Adolescent; Adult; Aspirin; Blood Platelets; Blood Vessel Prosthesis; Child; Dipyridamole; Evaluatio | 1982 |
[Inhibition of platelet function in pediatric medicine (author's transl)].
Topics: Age Factors; Aspirin; Child; Dipyridamole; Glomerulonephritis; Graft Rejection; Heart Defects, Conge | 1982 |
CarboMedics valve in congenital heart disease. Midterm follow-up study of 14 patients.
Topics: Aortic Valve; Aspirin; Child; Dipyridamole; Female; Follow-Up Studies; Heart Defects, Congenital; He | 1994 |
The role of anticoagulation in the development of pericardial effusion and late tamponade after cardiac surgery.
Topics: Adult; Anticoagulants; Aspirin; Cardiac Surgical Procedures; Cardiac Tamponade; Coronary Artery Bypa | 1993 |
Use of acetylsalicylic acid to improve patency of subclavian to pulmonary artery Gore-Tex shunts.
Topics: Aspirin; Blood Vessel Prosthesis; Female; Heart Defects, Congenital; Humans; Infant; Male; Polytetra | 1993 |
Cerebrovascular events in adult patients with cyanotic congenital heart disease.
Topics: Adult; Aged; Anemia, Iron-Deficiency; Anticoagulants; Aspirin; Atrial Fibrillation; Cerebrovascular | 1996 |
Reduced frequency of occlusion of aorto-pulmonary shunts in infants receiving aspirin.
Topics: Aorta; Arteriovenous Shunt, Surgical; Aspirin; Case-Control Studies; Female; Graft Occlusion, Vascul | 1999 |
Medical treatment of the ductus arteriosus.
Topics: Animals; Aspirin; Coronary Circulation; Ductus Arteriosus; Ductus Arteriosus, Patent; Fetal Heart; F | 1977 |
Effects of prostaglandins and blockers of prostaglandin synthesis on the ductus arteriosus: animal and human studies.
Topics: Animals; Aspirin; Ductus Arteriosus; Fetus; Heart Defects, Congenital; Humans; Infant, Newborn; Musc | 1978 |
[Hamostasiological changes induced by platelet-aggregation-inhibitors, tested in children with congenital heart disease (in vitro and in vitro examinations) (author's transl)].
Topics: Adolescent; Aspirin; Child; Child, Preschool; Cyanosis; Dipyridamole; Heart Defects, Congenital; Hem | 1976 |
Maternal hyperthermia during pregnancy and cardiovascular malformations in the offspring.
Topics: Aspirin; Data Collection; Female; Fever; Finland; Heart Defects, Congenital; Humans; Infant, Newborn | 1991 |
From the National Institutes of Health.
Topics: Aspirin; Breast Neoplasms; Female; Fetal Diseases; Heart Defects, Congenital; Humans; Immunotherapy; | 1990 |
The relation of aspirin use during the first trimester of pregnancy to congenital cardiac defects.
Topics: Abnormalities, Drug-Induced; Aortic Coarctation; Aortic Valve Stenosis; Aspirin; Case-Control Studie | 1989 |
Congenital heart disease in relation to maternal use of Bendectin and other drugs in early pregnancy.
Topics: Acetaminophen; Adult; Anti-Bacterial Agents; Antiemetics; Aspirin; Dicyclomine; Doxylamine; Drug Com | 1985 |
Problems associated with the screening of drugs for possible teratogenic activity.
Topics: 2,4,5-Trichlorophenoxyacetic Acid; Abnormalities, Drug-Induced; Animals; Aspirin; Dose-Response Rela | 1974 |
Sporadic malformations in laboratory animals and their influence on drug testing.
Topics: Abnormalities, Drug-Induced; Animals; Animals, Laboratory; Aspirin; Bone and Bones; Congenital Abnor | 1972 |